S. Kiani, Waheed Ashraf, M. Khan, A. Chaudhry, N. Azad, Waheed Ul Rehman, A. Zafar
{"title":"The Role of High-sensitive C-Reactive Protein in predicting Severity of Coronary Artery Disease in Patients with Acute Coronary Syndromes","authors":"S. Kiani, Waheed Ashraf, M. Khan, A. Chaudhry, N. Azad, Waheed Ul Rehman, A. Zafar","doi":"10.47144/phj.v56i1.2468","DOIUrl":null,"url":null,"abstract":"Objectives: We investigated the correlation between baseline C-reactive protein (Hs-CRP) levels and severity of coronary artery disease (CAD), measured in terms of Syntax Score (SScore), among patients presenting with acute coronary syndromes (ACS).\nMethodology: This cross-sectional study was conducted at the Armed Forces Institute of Cardiology (AFIC), Rawalpindi, from April 2022 to October 2022. Baseline Hs-CRP levels were obtained for all the patients. Patients were divided into three groups as per the SScore as low (≤ 22), intermediate (≥ 23), and high (≥ 33) burden of CAD.\nResults: Out of the 200 patients studied, 82.5% (165) were males, and mean age was 60.16±10.66 years. Diabetics were 50% (100) of the sample, 48.5% (97) were hypertensive, and smokers were 17.5% (35). Median Hs-CRP was 4.0 mg/L [2.0-12.5 mg/L], and median left ventricular ejection fraction (LVEF) was 45% [40-55%]. Median SScore was 23.5 [14.5-30.0], with 44.5% (89) categorized as low, 36.5% (73) as intermediate, and 19% (38) as high burden of CAD. The correlation between Hs-CRP and SScore was 0.236 (p=0.001) and -0.229 (p=0.001) with LVEF. A significant increase in Hs-CRP was observed in relation to the burden of CAD (p<0.001) with median of 2.0 mg/L [1.0-4.2 mg/L], 6.0 mg/L [3.1-15.7 mg/L], and 12.5 mg/L [5.8-20.7 mg/L] for low, intermediate, high burden of CAD, respectively.\nConclusion: Admission Hs-CRP was found to be positively correlated with the burden of CAD and negatively correlated with LVEF in patients with ACS.","PeriodicalId":42273,"journal":{"name":"Pakistan Heart Journal","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47144/phj.v56i1.2468","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: We investigated the correlation between baseline C-reactive protein (Hs-CRP) levels and severity of coronary artery disease (CAD), measured in terms of Syntax Score (SScore), among patients presenting with acute coronary syndromes (ACS).
Methodology: This cross-sectional study was conducted at the Armed Forces Institute of Cardiology (AFIC), Rawalpindi, from April 2022 to October 2022. Baseline Hs-CRP levels were obtained for all the patients. Patients were divided into three groups as per the SScore as low (≤ 22), intermediate (≥ 23), and high (≥ 33) burden of CAD.
Results: Out of the 200 patients studied, 82.5% (165) were males, and mean age was 60.16±10.66 years. Diabetics were 50% (100) of the sample, 48.5% (97) were hypertensive, and smokers were 17.5% (35). Median Hs-CRP was 4.0 mg/L [2.0-12.5 mg/L], and median left ventricular ejection fraction (LVEF) was 45% [40-55%]. Median SScore was 23.5 [14.5-30.0], with 44.5% (89) categorized as low, 36.5% (73) as intermediate, and 19% (38) as high burden of CAD. The correlation between Hs-CRP and SScore was 0.236 (p=0.001) and -0.229 (p=0.001) with LVEF. A significant increase in Hs-CRP was observed in relation to the burden of CAD (p<0.001) with median of 2.0 mg/L [1.0-4.2 mg/L], 6.0 mg/L [3.1-15.7 mg/L], and 12.5 mg/L [5.8-20.7 mg/L] for low, intermediate, high burden of CAD, respectively.
Conclusion: Admission Hs-CRP was found to be positively correlated with the burden of CAD and negatively correlated with LVEF in patients with ACS.